Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

U.S. suspends Ixchiq vaccine license due to serious side effects, raising concerns over chikungunya virus spread globally.

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

US health authorities have suspended the licence of the Ixchiq vaccine, used against the mosquito-borne chikungunya virus, after reports of serious side effects in several patients, including elderly ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.